Cibus Inc Ordinary Shares - Class A CBUS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CBUS is a good fit for your portfolio.
News
-
Canada Added to a Growing List of Countries Regulating Cibus’ Gene Editing Technologies Similar to Conventional Breeding
-
Cibus to Participate in the BMO Global Farm to Market Conference
-
Cibus Reports First Quarter Financial Results and Provides Business Update
-
Cibus to Report First Quarter 2024 Financial Results on May 9, 2024 and Host Conference Call
-
Cibus Reports Fourth Quarter Financial Results and Provides Business Update
-
Cibus Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2024
-
Cibus to Participate in the 36th Annual Roth Conference
-
Cibus to Report Fourth Quarter 2023 Financial Results on March 21, 2024 and Host Conference Call
Trading Information
- Previous Close Price
- $18.70
- Day Range
- $18.36–18.75
- 52-Week Range
- $8.90–38.85
- Bid/Ask
- $14.01 / $18.50
- Market Cap
- $453.51 Mil
- Volume/Avg
- 48 / 67,822
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 121.01
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 183
- Website
- https://www.cibus.com
Comparables
Valuation
|
Metric
|
CBUS
|
PTGX
|
EQRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 13.09 | — |
Price/Book Value | 1.39 | 3.34 | 0.97 |
Price/Sales | 121.01 | 6.09 | — |
Price/Cash Flow | — | 10.01 | — |
Price/Earnings
CBUS
PTGX
EQRX
Financial Strength
|
Metric
|
CBUS
|
PTGX
|
EQRX
|
|---|---|---|---|
Quick Ratio | 1.16 | 15.61 | 18.43 |
Current Ratio | 1.23 | 15.72 | 18.78 |
Interest Coverage | −12.22 | — | — |
Quick Ratio
CBUS
PTGX
EQRX
Profitability
|
Metric
|
CBUS
|
PTGX
|
EQRX
|
|---|---|---|---|
Return on Assets (Normalized) | −17.68% | 51.28% | −15.72% |
Return on Equity (Normalized) | −31.45% | 56.32% | −16.71% |
Return on Invested Capital (Normalized) | −18.80% | 51.24% | −21.31% |
Return on Assets
CBUS
PTGX
EQRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Kvmcsxjtd | Kygln | $593.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dyncpqxp | Vghjzt | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bdnkzlpm | Bxqkbxf | $106.7 Bil | |
MRNA
| Moderna Inc | Scfkzfvkm | Vdzhf | $50.8 Bil | |
BNTX
| BioNTech SE ADR | Wqxlgzg | Csqg | $22.4 Bil | |
ARGX
| argenx SE ADR | Lvfxrfrdy | Cnz | $22.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pcvtllbk | Ffmcsvv | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Myrpdrnb | Kkhhnzm | $14.6 Bil | |
INCY
| Incyte Corp | Jrjwwpzv | Mtjhbs | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Brnjpjqfb | Rnmgxk | $12.6 Bil |